Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Single-group, Multi-center, Phase II Clinical Trial Evaluating the Effect of Maintenance DCVAC/OvCa After Standard-of-care Therapy in Women With First Relapse of Platinum-sensitive Epithelial Ovarian Cancer

Trial Profile

An Open-label, Single-group, Multi-center, Phase II Clinical Trial Evaluating the Effect of Maintenance DCVAC/OvCa After Standard-of-care Therapy in Women With First Relapse of Platinum-sensitive Epithelial Ovarian Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2018

At a glance

  • Drugs DCVAC OvCa (Primary) ; Carboplatin; Gemcitabine; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Sponsors SOTIO
  • Most Recent Events

    • 05 Nov 2018 Status changed from recruiting to active, no longer recruiting.
    • 01 Dec 2017 New trial record
    • 28 Nov 2017 This trial is conducted in collaboration with CEEGOG (Central and Eastern European Gynecological Oncology Group), as reported in a SOTIO media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top